Gyre Therapeutics, Inc. Common Stock (GYRE) is a publicly traded Healthcare sector company. As of May 21, 2026, GYRE trades at $6.11 with a market cap of $624.86M and a P/E ratio of 100.58. GYRE moved +0.00% today. Year to date, GYRE is -23.74%; over the trailing twelve months it is -47.02%. Its 52-week range spans $6.01 to $19.00. Analyst consensus is buy with an average price target of $19.00. Rallies surfaces GYRE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes GYRE SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $6.11 |
| Market Cap | $624.86M |
| P/E Ratio | 100.58 |
| EPS | $0.06 |
| Dividend Yield | 0.24% |
| 52-Week High | $19.00 |
| 52-Week Low | $6.01 |
| Volume | 11.54K |
| Avg Volume | 0 |
| Revenue (TTM) | $116.59M |
| Net Income | $9.88M |
| Gross Margin | 95.36% |
2 analysts cover GYRE: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $19.00.